BI Asset Management Fondsmaeglerselskab A S Sells 67,695 Shares of Gilead Sciences, Inc. $GILD

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

BI Asset Management Fondsmaeglerselskab A S lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.5% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 398,811 shares of the biopharmaceutical company's stock after selling 67,695 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Gilead Sciences were worth $44,687,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of GILD. Brighton Jones LLC grew its position in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 2,450 shares during the period. Gabelli Funds LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at $387,000. Transce3nd LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at $99,000. Harvest Investment Services LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at $304,000. Finally, Alta Advisers Ltd grew its position in Gilead Sciences by 16.4% in the 4th quarter. Alta Advisers Ltd now owns 4,192 shares of the biopharmaceutical company's stock valued at $387,000 after purchasing an additional 592 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $296,325.00. Following the sale, the chief financial officer directly owned 160,110 shares in the company, valued at $18,977,838.30. The trade was a 1.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares in the company, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 82,000 shares of company stock valued at $9,339,230. 0.27% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on GILD. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a research report on Tuesday. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a report on Friday, August 8th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a report on Friday, July 25th. Oppenheimer cut their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Finally, Morgan Stanley lifted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $2.59 during mid-day trading on Thursday, reaching $116.14. 6,062,069 shares of the company's stock were exchanged, compared to its average volume of 6,678,418. The firm has a market capitalization of $144.11 billion, a price-to-earnings ratio of 23.14, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. Gilead Sciences, Inc. has a 52 week low of $75.35 and a 52 week high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm has a 50-day moving average price of $112.41 and a two-hundred day moving average price of $108.90.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the previous year, the business posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences's payout ratio is presently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.